BioRestorative Therapies

03/19/2026

announces new, blinded data on ~45 patients from its Phase 2 evaluating hypoxic-cultured mesenchymal for the treatment of chronic lumbar disc disease.

These data have been accepted for presentation at the 2026 Orthopaedic Research Society Annual Meeting, which will be held March 27-31, 2026, at the Charlotte Convention Center in Charlotte, North Carolina.

Full press release here: https://ir.biorestorative.com/news-events/press-releases/detail/238/biorestorative-therapies-to-present-positive-phase-2-blinded-data-for-brtx-100-demonstrating-meaningful-improvements-in-pain-and-function-in-chronic-lumbar-disc-disease

03/17/2026

, read the latest letter to shareholders from CEO, Lance Alstodt. He details the primary focus and goals for 2026 including advancing BRTX-100 into late-stage development with regulatory clarity and operational readiness for BLA approval.

Read what plans to achieve in terms of clinical programs, regulatory strategy, commercial initiatives, and capital positioning.

Learn more: https://ir.biorestorative.com/news-events/press-releases/detail/236/biorestorative-therapies-inc-issues-letter-to-shareholders-highlighting-major-milestones-regulatory-alignment-clinical-execution-and-capital-strategy

U.S. Food and Drug Administration

03/11/2026

The commercial leadership team had a great time participating in IBS & Be+Well Beauty and Wellness Shows' latest event at the Javits Center in New York City.

Check out a few snapshots of our team at one of the largest professional beauty, spa, and wellness trade events in the U.S., including our scientifically validated exosomes being delivered below the skin surface using JetPeel by TavTech technology!

NYLO Aesthetics

03/10/2026

Each year, over 25 million Americans suffer from chronic lower back pain and yet, traditional treatments are failing. BRTX-100 may offer a new path forward. Our single-injection therapy uses the patient’s own scientifically enhanced stem cells to directly target and begin repairing the damaged disc.

Learn more about phase 2 here: biorestorative.com/brtx-100-2

U.S. Food and Drug Administration

06/18/2025

https://www.globenewswire.com/news-release/2025/06/18/3101583/0/en/BioRestorative-to-Participate-in-Benzinga-All-Access-Show-Today-to-Discuss-Compelling-BRTX-100-Clinical-Data-Leadership-Enhancements-and-Strategic-updates.html

MELVILLE, N.Y., June 18, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical...

06/17/2025

https://www.globenewswire.com/news-release/2025/06/17/3100770/0/en/BioRestorative-Announces-Share-Repurchase-Program.html

MELVILLE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical...

06/13/2025

https://ir.biorestorative.com/news-events/press-releases/detail/218/biorestorative-reports-compelling-preliminary-data-for-fda-fast-tracked-brtx-100-an-autologous-stem-cell-therapy-to-treat-chronic-lumbar-disc-disease

– The International Society for Stem Cell Research (“ISSCR”) 2025 Annual Meeting is the world’s foremost gathering of stem cell…...

06/09/2025

https://www.globenewswire.com/news-release/2025/06/09/3095762/0/en/BioRestorative-to-Present-Major-Update-on-Promising-Preliminary-Phase-2-BRTX-100-Data-at-ISSCR-2025.html

– New blinded safety and efficacy data from 30 patients in ongoing Phase 2 trial to be unveiled June 13, 2025 – – ISSCR 2025 is the premier global event...

08/13/2024

08/03/2024

biorestorative.com

07/25/2024

If you suffer from lower back pain please click the link below to learn more about our clinical trial using stem cell therapy

Clinical Trial